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LYMPHOID NEOPLASIA
Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct
subgroup with poor prognosis
*Javeed Iqbal,1 *Yulei Shen,1 *Yanyan Liu,1 Kai Fu,1 Elaine S. Jaffe,2 Cuiling Liu,1 Zhongfeng Liu,1 Cynthia M. Lachel,1
Karen Deffenbacher,1 Timothy C. Greiner,1 Julie M. Vose,3 Sharathkumar Bhagavathi,1 Louis M. Staudt,4 Lisa Rimsza,5
Andreas Rosenwald,6 German Ott,7 Jan Delabie,8 Elias Campo,9 Rita M. Braziel,10 James R. Cook,11 Raymond R. Tubbs,11
Randy D. Gascoyne,12 James O. Armitage,3 Dennis D. Weisenburger,1 Timothy W. McKeithan,3 and Wing C. Chan1
1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; 2Laboratory of Pathology, Center for Cancer Research,
National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 3Department of Hematology/Oncology, University of Nebraska Medical
Center, Omaha, NE; 4Metabolism Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD; 5Department of Pathology, University of Arizona, Tucson,
AZ; 6Department of Pathology, University of Wu¨rzburg, Wu¨rzburg, Germany; 7Department of Clinical Pathology, Dr Margarete Fischer Bosch Institute of Clinical
Pharmacology, Robert Bosch Hospital, Stuttgart, Germany; 8Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway;
9Hospital Clinic, University of Barcelona, Barcelona, Spain; 10Department of Clinical Pathology, Oregon Health and Science University, Portland, OR;
11Department of Molecular Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH; and 12Center for Lymphoid Cancer, British Columbia Cancer
Agency, Vancouver, BC
miRNA deregulation has been implicated
in the pathogenesis of mantle cell lym-
phoma (MCL). Using a high-throughput
quantitative real-time PCR platform, we
performed miRNA profiling on cyclin
D1–positive MCL (n  30) and cyclin
D1–negative MCL (n  7) and compared
them with small lymphocytic leukemia/
lymphoma (n  12), aggressive B-cell lym-
phomas (n  138), normal B-cell subsets,
and stromal cells. We identified a 19-miRNA
classifier that included 6 up-regulated
miRNAs and 13 down regulated miRNA
that was able to distinguish MCL from
other aggressive lymphomas. Some of
the up-regulated miRNAs are highly ex-
pressed in naive B cells. This miRNA classi-
fier showed consistent results in formalin-
fixed paraffin-embedded tissues and was
able to distinguish cyclin D1–negative
MCL from other lymphomas. A 26-miRNA
classifier could distinguish MCL from
small lymphocytic leukemia/lymphoma,
dominated by 23 up-regulated miRNAs in
MCL. Unsupervised hierarchical cluster-
ing of MCL patients demonstrated a clus-
ter characterized by high expression of
miRNAs from the polycistronic miR17-92
cluster and its paralogs, miR-106a-363
and miR-106b-25, and associated with
high proliferation gene signature. The
other clusters showed enrichment of
stroma-associated miRNAs, and also had
higher expression of stroma-associated
genes. Our clinical outcome analysis in
the present study suggested that miRNAs
can serve as prognosticators. (Blood.
2012;119(21):4939-4948)
Introduction
Mantle cell lymphoma (MCL) constitutes approximately 6% of all
nonHodgkin lymphomas and occurs predominantly in men of
advanced age.1,2 Several histologic variants of MCL, including the
classic, small-cell, blastoid, and pleomorphic variants, have been
reported1 and have various proliferation rates and genetic pro-
files.3,4 The putative cell-of-origin is considered to be a naive B cell
in the mantle zones or primary follicles. However, 20%-30% of
patients show mutated immunoglobulin variable-region heavy
chain (IGVH) genes.2 The immunophenotype is characterized by
expression of CD5 and the B cell–associated antigens CD20,
CD22, CD79, and CD5, with strong expression of IgM and IgD,
but by the lack of CD23, CD10, and BCL6.1,2 Historically, the
majority of MCL patients exhibit an aggressive clinical course, but
survival has improved with current management to a reported
median survival time of 5-7 years.5 Recent studies have identified
an indolent subtype of MCL that is associated with even longer
survival times.6-7 The neoplastic cells in these patients exhibit
hypermutated IGVH genes, a noncomplex karyotype, and lack
SOX11 expression.
The genetic hallmark of MCL is the t (11;14)(q13;q32) muta-
tion, resulting in the overexpression of cyclin D1. Nonetheless,
small subsets of patients ( 5%) lack this genetic aberration but
exhibit an almost indistinguishable gene-expression profile (GEP)
and genomic profile compared with cyclin D1–positive patients.8,9
Several recurrent genetic abnormalities have been reported in
MCL, including frequent losses of 9p21.3, 11q22-q23, and 22q11.22,
and gains of 10p11.23 and 13q31.3.3,4,9 Specific mutations and
deletions in p16 (CDKN2A), ATM, CHEK2, and TP53 have also
been noted frequently in MCL.2 Partial uniparental disomy has also
been reported in the regions that are frequently targeted by
chromosomal deletions.10
Abnormal miRNA expression has been implicated in the
pathogenesis of lymphoma, including the recurrent 13q31.3 gain9
harboring MIHG1, which encodes the miR17-92 cluster composed
of 6 polycistronic miRNAs (miR-17, miR-18a, miR-19a, miR19b-1,
miR-20a and miR-92a). Alteration in miRNA expression has been
explored in B-cell lymphomas including MCL.11-13 In the present
study, we performed a large-scale global analysis on multiple types
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of B-cell lymphoma to compare with MCL using an miRNA
profiling platform based on high-throughput Taqman quantitative
real-time RT-PCR. The study was aimed at identifying diagnostic
and prognostic signatures in MCL, including cyclin D1–positive
and cyclin D1-negative patients. The quantitative RT-PCR assay
permits highly accurate quantitation of individual miRNAs over a
wide dynamic range and distinguishes between closely related
miRNA family members. We also explored the applicability of this
platform to both cryopreserved and formalin-fixed paraffin-
embedded (FFPE) tissues. We also compared the miRNA profiles
with the corresponding GEP data to investigate the molecular
mechanisms or pathways associated with deregulated miRNA
expression.
Methods
Patient samples, cell lines, and normal primary cells
Frozen tumor specimens and fresh tonsils from routine tonsillectomy were
obtained from patients under a protocol approved by the institutional review
board of the University of Nebraska Medical Center (Omaha, NE). Tumor
biopsies taken from a series of cyclin D1–positive mantle cell lymphoma
(MCL) patients (n 30) and small lymphocytic lymphoma/chronic lympho-
cytic leukemia (SLL/CLL) patients (n  12) were studied for miRNA and
gene-expression profiling (GEP). We compared these miRNA/GEP results
with a series of diffuse large B-cell lymphoma (DLBCL) and Burkitt
lymphoma (BL) patients (n  138). We compared miRNA profiles obtained
from cryopreserved tissues with corresponding FFPE tissues in 8 (of 30)
MCL samples and 35 (of 138) DLBCL/BL samples. The other FFPE
samples included cyclin D1–negative MCL (n  7) and GEP for 6 patients
have been reported previously.8,14 A panel of expert hematopathologists
reviewed and confirmed the diagnosis of patients using the World Health
Organization classification.1 The experimental details about cell lines and
primary B cells are included in supplemental Methods (available on
the Blood Web site; see the Supplemental Materials link at the top of the
online article).
The detailed protocol on RNA isolation from fresh frozen and FFPE
tissues for miRNA and/or GEP, miRNA profiling and GEP data analysis,
immunologic and FISH analysis, and survival outcome analysis are
available in supplemental Methods.
Results
Patient characteristics
The clinical characteristics of the MCL and SLL patients are
summarized in Table 1. The median age of the MCL patients
(n  30) was 63 years (range, 37-88) at the time of diagnosis with a
high ratio of male to female patients (5:1). These MCL patients
exhibited an aggressive clinical course with a median overall
survival (OS) of 2.98 years (supplemental Figure 1). These patients
were also profiled for GEP and were classified as MCL with 90%
confidence. Most of the patients were CD5 and/or CD43 and
expressed cyclin D1 or showed cyclin D1 translocation by FISH
(supplemental Table 1A).
Of the other MCL patients (n  7) who were negative for
t(11;14) and cyclin D1 expression, the GEP of 6 has been reported
previously.8 The seventh patient, without GEP, showed MCL
morphology and SOX11 expression consistent with other t(11;14)–
negative MCL patients. Similar to cyclin D1–positive MCL
patients, the median age at the time of diagnosis was 60 years
(range, 51-65) with male predominance (5 of 7 patients), and also
showed a similar immunophenotype, with expression of B-cell
markers and CD5. The expression of SOX11 (7 of 7), cyclinD2
(3 of 5), or D3 (2 of 5) was noted in the cyclin D1–negative patients
(supplemental Table 1B).
The median age of the SLL/CLL patients was 59 years (range,
40-90 years) at the time of diagnosis, with a ratio of male to female
patients of 2:1. These patients had the characteristic morphology
and immunophenotype, including a lack of cyclin D1 expression.
The majority (70%) of SLL/CLL patients had not received any
chemotherapy and the median follow-up time from diagnosis was
6.2 years.
Molecular classifier for MCL based on miRNA profile
Unsupervised hierarchical clustering (HC) analysis revealed that
the MCL and SLL patients formed a distinct cluster compared with
other lymphoma entities (Figure 1A). Of the 30 MCL and
12 SLL/CLL patients, only one each clustered separately in the
DLBCL cluster. However, both patients were classified molecu-
larly as MCL or SLL with the miRNA classifiers after further
analysis (see paragraph below), indicating that the tumors still
maintained a substantial differentiation-associated miRNA profile.
Further examination of the miRNA profile showed that
2 prominent miRNA signatures were differentially expressed
among the major lymphoma entities: one signature reflected
miRNAs highly expressed in stromal cells that were more highly
expressed in DLBCL and BL. The other signature was associated
with nondividing, quiescent cells (naive, resting peripheral blood
cells) and was highly represented in MCL or SLL/CLL patients.
These observations are consistent with the morphologic findings
that MCL lacks a major stromal component compared with
DLBCL and that most MCL cases are not as proliferative as other
aggressive lymphomas.
We used a Bayesian algorithm to derive a miRNA classifier that
differentiates MCL from DLBCL/BL and leave-one-out cross-
validation for classification precision.15 This algorithm resulted in a
19-miRNA classifier, which included 6 up-regulated miRNAs
Table 1. Characteristics of MCL (cyclin D1–positive) and SLL
patients included in the study*
Clinical feature MCL n  30 SLL n  12
Median age, y (range) 63 (37-88) 59 (40-90)
Sex, n (%)
Female 5 (17) 3 (27)
Male 25 (83) 8 (63)
Performance score, n (%)
 70 3 (10) 0 (0)
 70 27 (90) 11 (100)
Stage
I/II 2 (6) 2 (18)
III/IV 28 (94) 9 (82)
Serum lactate dehydrogenase, n (%)
Normal 21 (70) 9 (82)
Elevated 9 (30) 2 (11)
No. of extranodal sites, n (%)
 2 26 (87) 10 (91)
 2 4 (13) 1 (9)
Median survival, y
OS 3.0
EFS 1.5 6.2
EFS indicates event-free survival.
*The characteristics of 6 (of 7) cyclin D1–negative MCL patients have been
described previously8; the seventh case, without GEP, showed MCL morphology and
SOX11 expression consistent with other t(11;14)–negative MCL patients. One of the
12 SLL patients lacked complete clinical data.
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(miR-135a, miR-708, miR-150, miR-363, miR-184, and miR-342-
5p) and 13 down-regulated miRNAs (Figure 1B). When this
signature was evaluated in normal B-cell subsets, the majority of
the up-regulated miRNAs were also highly expressed in naive
B cells, resting B cells, or CC cells, with the exception of
miR-135a and miR-708, which were normally more highly ex-
pressed by CB/CC and stromal cells, respectively. However, they
were also expressed by 2 MCL cell lines, JEKO and JVM2. The
majority (8 of 13) of down-regulated miRNAs (miR-424, miR-382,
miR-376c, miR-127-3p, miR-539, miR-379, miR-376a, and miR-
411) were expressed by stromal cells at a high level, which is
consistent with a low stromal content in MCL. The expression of
the other down-regulated miRNAs was also low in naive and
resting B cells.
Morphologic evaluation of the discrepant patients identified by
miRNA classifier
We evaluated the precision of the miRNA classifier by leave-one-
out cross-validation and observed that 2 patients defined by GEP as
Figure 1. MicroRNA expression profile and classifier for MCL. (A) Unsupervised hierarchical clustering of lymphoma samples, normal cells, and cell lines. MCL, SLL,
DLBCL, and BL formed largely distinct clusters. A stromal cell–associated miRNA signature was more highly expressed in DLBCL and BL patients. There were also significant
differences in the expression of miRNA associated with naive B cells, resting B cells, CB cells, and CC cells, with miRNA associated with naive and resting B cells being more
highly represented in MCL and SLL patients. (B) An miRNA classifier derived using a Bayesian algorithm resulted in a 19-miRNA classifier (6 up-regulated and
13 down-regulated miRNAs) was able to separate most MCL patients from DLBCL and BL patients. The expression of this miRNA classifier is illustrated in SLL, normal cells,
and cell lines. Orange boxes highlight naive B-cell and MCL cell lines.
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DLBCL (n  89) were misclassified as MCL with a  90%
probability. These 2 patients were classified as ABC-DLBCL
(n  1) and unclassifiable-DLBCL (n  1) by GEP analysis.
However, after further review, the morphology of these patients
was compatible with the paraimmunoblastic variant of SLL. In
general, SLL/CLL patients had a high association (80%-90%
probability) with the MCL classifier and therefore required a
separate analysis (see “Comparison of miRNA expression profile
between MCL and SLL”).
Only one MCL patient showed probability  90% by the
miRNA classifier (Figure 1B). This patient was different from the
other one that clustered within DLBCL patients in unsupervised
HC (Figure 1A), but by miRNA classifier showed 95% probabil-
ity as MCL. After review, this patient was shown to have
blastoid-variant morphology.
Comparison of miRNA expression profile between MCL and SLL
As expected from the close clustering of MCL and SLL patients
(Figure 1A), the miRNAs in the MCL classifier (derived from
comparison with DLBCL/BL) showed significant overlap with the
SLL patients, with the exception of 4 miRNAs (miR-363, miR-184,
miR-708, and miR-135a) that were highly expressed in MCL
(Figure 1B). When only the MCL and SLL patients were analyzed
by unsupervised HC, 2 separate clusters (A and B) of SLL (Figure
2A) were observed. The SLL cluster A showed mainly up-regulated
miRNAs compared with patients in cluster B and was characterized
by high expression of miRNAs shown to have a tumor-suppressive
function (miR-1, miR-133a,16 miR-133b,16 miR-139-5p, miR-139-
3p, miR-143,17 miR-10b,18 miR-145,16 and miR-23b) and stroma-
related (miR-23a, miR-27a, miR-27b, miR-152, and miR-221).
One each of 2 paraimmunoblastic SLL patients (identified above),
clustered with SLL cluster A and cluster B, and showed no
association with MCL clusters.
To separate MCL and SLL more definitively, we constructed a
classifier consisting of 26 miRNAs that was dominated by
23 miRNAs up-regulated in MCL, including miR-184 and mem-
bers of 2 polycistronic miRNA clusters, miR106b-25 (miR-106b
and miR-25) and miR106a-363 (miR-363 and miR-20b), which are
paralogs of the miR17-92 cluster. In the classifier, only miR-150,
miR-511, and miR-375 were up-regulated significantly in SLL
patients (Figure 2B). Five MCL patients showed a probability of
 90% (40%-70% for 4 patients and 20% for 1 patients) and
1 patient was classified as SLL, suggesting that a small subset of
MCL patients may have a miRNA profile very similar to SLL
patients. The latter 2 patients showed low expression of the
proliferation gene signature (PS; log2 signal intensity 7.3, 7.6; range in
30 patients of PS is 6.9-9.1), and were part of the indolent MCL
patient cluster (see “Identification of MCL subsets by miRNA
profiling and correlation with GEP signatures”). Interestingly the
2 SLL paraimmunoblastic variants, despite their much higher
proliferation, showed significant similarity with the SLL group
(80% and 90% probability, respectively) in their miRNA expres-
sion profile (Figure 2B)
Identification of MCL subsets by miRNA profiling and
correlation with GEP signatures
When MCL patients alone were analyzed by unsupervised HC,
3 distinct clusters were observed (Figure 3A) with a significant
difference in expression of 95 miRNAs (P  .005) among these
clusters. We applied previously defined MCL PS19 and observed a
significant difference (P  .01 by Kruskal-Wallis Test) in the
median expression of PS among the 3 miRNA-defined clusters,
designated as cluster A (high PS), cluster B (medium PS), and
cluster C (low PS; Figure 3A). The difference was more prominent
between clusters A and C. The patients in cluster A showed
up-regulation of miR17-92 cluster members and its paralogs
miR-106a-363 and miR-106b-25, which is indicative of a prolifera-
tive miRNA profile and a subgroup of miRNAs closely associated
with the CB, CC, and cell lines, but not with naive B cells (Figure
3B). The patients in cluster C showed up-regulation of miRNA with
growth-inhibitory functions including miR-1, miR-133b,16 miR-
10b,18 and stroma-associated markers (miR-23a, miR-23b, let-7c,
Figure 2. Differences in miRNA expression between MCL and SLL. (A) Unsupervised hierarchical clustering of MCL and SLL samples showed 2 separate clusters of SLL
patients with each having unique miRNA profiles. (B) A 26-miRNA signature differentiates MCL from SLL, with 23 miRNAs including 2 polycistronic miRNA clusters,
miR106b-25 (miR-106b and miR-25) and miR106a-363 (miR-363 and miR-20b) being significantly up-regulated in MCL compared with SLL.
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let-7-b, and miR-125b). Of the differentially expressed miRNAs,
those associated with stroma were significantly enriched in cluster
C, illustrating the contribution of stroma in this subset of patients.
The cluster-B patients showed low expression of majority of the
miRNAs compared with clusters A and C, but high expression
of miRNAs associated with stroma (miR-636, miR-539, and
miR-485-3p) was noted specifically in this subset.
To further understand the biologic significance of these clusters,
we also examined the GEP data. Interestingly, GEP-based unsuper-
vised HC showed that patients placed in cluster A as defined by
miRNA profile were almost identical to 1 of the 3 subclusters
defined by GEP (all 8 patients in cluster A), supporting that patients
in cluster A had distinctive molecular characteristics. When GEP
data from the 3 miRNA-defined clusters were analyzed, 649 transcripts
showed significant differential expression (P  .005). Functional
analysis showed that transcripts encoding proteins with roles in
cell-cycle progression and proliferation or in inhibition of apopto-
sis were highly up-regulated in cluster A, which is consistent with
the association with a high PS (Figure 3C). The transcript level of
the proliferation marker Ki67 was associated significantly with this
group (P  .0001). In addition, we observed high expression of
genes encoding proteins secreted by macrophages (eg, CHI3L1),
including CD163 expressed in M2 macrophages, in this group. The
patients in cluster C (the low-PS group) showed relatively high
expression of genes encoding cytokines mainly associated with
T cells (CX3CL1, CXCL12, CXCL2, and CXCL5) and genes
associated with WNT signaling (FZD, WNT5A, and SFRP2)
compared with cluster A (the high-PS group). The patients in this
group also expressed transcripts encoding extracellular matrix–
related proteins (ECM2, EDN1, EGFR, EPS8, ITGA9, and PDGFD).
Interestingly, many up-regulated and down-regulated genes in
cluster C showed similar expression pattern in cluster
B, however, a unique gene signature was also noted in these
groups. Information on the functional characteristics of these genes
is limited in the literature (Figure 3C). Gene-set enrichment
analysis complemented these results, with significant enrichment
of the proliferation-related gene signatures in cluster A, whereas
both of the other clusters showed enrichment of IL-6, TGF-,
hypoxia, VEFG, Hox10-induced, and quiescent/stem cell–like
gene signatures. Compared with cluster C, cluster B had a higher
TGF- signature and showed more genotoxic stress with higher
p21 and ATM signatures, whereas cluster C showed higher
expression of WNT and IL-4 signaling pathway genes (supplemen-
tal Table 2). We performed immunohistochemistry with -catenin
on 3 representative patients from cluster C and 2 patients from
cluster A. We observed strongly positive expression of -catenin in
stromal/endothelial cells in all 3 patients from cluster C. The
majority of tumor cells were negative, whereas patients with a high
proliferation signature (cluster A) showed only the occasional cell
weakly positive for -catenin (supplemental Figure 3), indicating
that WNT activation may be attributed mostly to stromal compo-
nents in cluster C patients.
Validation of GEP signatures. To further validate the GEP
findings of these 30 MCL patients, we performed validation of the
Figure 3. Unsupervised hierarchical clustering of MCL patients showed 3 distinct MCL clusters. (A) Significant differences in the PS among the 3 groups (P  .01 by
Kruskal-Wallis test). PS included the same gene set identified in Rosenwald et al.19 (B) Differential miRNA expression (95 miRNAs, P  .005) among these clusters designated
as cluster A (associated with high PS), cluster B (medium PS), and cluster C (low PS). (C) Differential gene expression (649 transcripts, P  .005) among the 3 clusters, with
cluster A showing high expression of proliferation-associated genes and the other clusters showing higher expression of genes associated with stromal components.
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gene signatures in another cohort of MCL patients (n  82). In our
initial analysis, we derived a specific gene-expression signature
from the GEP data of the 30 MCL patients in this study (training
data) that could distinguish cluster A and cluster C patients using
Bayesian algorithm. This resulted in a 71-probe set with 2 gene
signatures, one enriched in proliferation-related genes (signature 1)
and the other enriched in stroma-related genes including WNT
pathway genes (signature 2), as shown in supplemental Figure 4A.
The mean expression levels of these 2 gene signatures were
inversely correlated and the ratio of the mean expression of the
2 signatures was associated significantly with event-free survival
(P  .01). We then analyzed the gene signatures in the independent
MCL series (n  82) using hierarchical clustering, and obtained
4 subsets of MCL patients, with the majority showing an inverse
correlation between signature 1 and 2 expression. However, a small
subset of patients expressed both signatures at similar levels (both
high and both low). There was a significant association of OS with
signature 1 that predicted a worse prognosis. When the ratio of
expression of the 2 signatures was correlated with OS, higher ratios
(signature 1 vs 2) were associated with poorer prognosis (supple-
mental Figure 4B).
Comparison of naive B cells and MCL miRNA profile and
functional implications
We identified a miRNA signature associated significantly with
naive B cells by comparison with other B-cell subsets, including
CCs and CBs (supplemental Figure 2). The miRNAs associated
significantly with naive B-cell subsets were miR-150, miR-223,
miR-342-3p, miR-146-5p, miR-95, miR-342-5p, and miR-146b-
3p, with at least 4 of the 7 miRNAs described in previous
studies.20-22 These up-regulated miRNAs were also observed in
resting B and T cells and showed marginal enrichment in MCL
patients compared with those with other lymphoid entities (data not
shown), but were largely absent from the lymphoid cell lines.
To identify miRNAs that may have pathogenetic significance,
we compared the miRNA profile of normal naive B cells with that
of MCL. Excluding differences that may be attributable to the
stromal elements, we observed that the majority ( 80%) of
differentially expressed miRNAs were up-regulated in MCL com-
pared with naive B cells (Figure 4). The miRNAs that were
up-regulated in MCL but not in naive B cells or stromal elements
included miR-184, miR-21, miR-10b, and miR-135a, the onco-
genic roles of which have been demonstrated in several malignan-
cies,23-26 but the functional characteristics of many other up-
regulated miRNAs is not known. Only a few miRNAs were
down-regulated in MCL cells compared with normal naive B cells;
however, these included some of the most abundant miRNAs
(miR-150, miR-223, miR-222, and miR342-5p/3p) in naive B cells,
suggesting that low expression of these miRNAs may be important
for the pathogenesis of MCL (Figure 4).
Evaluation of cryopreserved and FFPE miRNA profile
The miRNA classifier obtained from cryopreserved tissues was
evaluated in corresponding FFPE MCL (n  8) and DLBCL/BL
(n  35) patients. Of the 19 miRNAs, 2 showed inconsistent
expression in the FFPE samples, but the remaining 17 miRNAs
were able to distinguish MCLs from DLBCLs and BLs with similar
sensitivity and specificity. The expression pattern of this
17-miRNA signature was similar between cyclin D1–positive and
cyclin D1–negative MCL patients (n  7) and they readily distin-
guished from DLBCL/BL patients (Figure 5A).
Cyclin D1–negative versus cyclin D1–positive MCL. Despite
the substantial similarity in miRNA profiles, cyclin D1–positive
and cyclin D1–negative MCL patients clustered separately in
unsupervised HC, and showed 30 differentially expressed miRNAs
(P  .05 and 4-fold differences; Figure 5B-C). The differences
included down-regulation of miRNAs negatively regulated by
MYC (miR-15a, miR-22, miR-29a, miR-29b, miR-29c, and miR-
142-3p)27 and up-regulation of the oncomiR miR-15528 in cyclin
D1–negative MCL patients. In contrast, cyclin D1–positive pa-
tients showed significant up-regulation of miR-27 and miR-19a,
suggesting some distinct pathogenetic features in these 2 subgroups
of MCL. In addition, we did not observe significant expression
changes of miRNAs located on 11q13 (miR-1237, miR-192,
miR-194-2, miR-612, miR-548, miR-139, and miR-326) encom-
passing the CCND1 locus between cyclin D1–positive and cyclin
D1–negative MCL patients.
Figure 4. Comparison of the MCL miRNA profile with
other B-cell subsets, T-cells, and stromal elements.
More than 80% of differentially expressed (P  .005)
miRNAs were up-regulated in MCL cells compared with
naive B cells.
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Association of miRNA profile with clinical outcome
The correlation of miRNA expression with clinical outcome was
evaluated by correlation with the mRNA-based proliferation signa-
ture and by the Bair et al29 unsupervised principle to identify
miRNAs that predict OS or event-free survival with PS as a
covariate in the analysis. When miRNAs were analyzed with
respect to the mRNA-based PS, 28 miRNAs were significantly
(P  .05) differentially expressed between the highest-tertile
(n  10) and lowest-tertile (n  10) proliferative subgroups (Fig-
ure 6A). The high-proliferative group is characterized by high
expression of miR-18a of the miR17-92 cluster and miR-18b,
miR-20b, and miR-363 of the miR-106a-363 cluster, indicating a
proliferative miRNA signature.30,31 The low-proliferative group
included higher expression of miR-125-3p, miR-126, miR-10b,
miR-143, and miR-145, many of which are highly expressed in
stromal cells, suggesting that the low-proliferative group is associ-
ated with a higher microenvironment signature.
We also performed survival risk prediction and a multivariate
proportional hazards model was developed using PS as one of the
covariates. We identified a 6-miRNA signature (high expression of
miR129-3p, miR-135a, miR-146a, miR-424, and miR-450-5p and
low expression of miR-222), separating MCL into good (median
OS, approximately 4 years) and poor (median OS, approximately
2 years) prognostic groups independently of miRNAs associated
with PS (Figure 6C and supplemental Table 3B).
Figure 5. miRNA expression in cyclin D1–positive
and –negative MCL. (A) MCL classifier obtained from
cryopreserved tissues showed similar predictive power in
FFPE tissues and cyclin D1–negative MCL classified as
MCL. (B) Unsupervised clustering based on miRNA
profiles showed distinct clusters of cyclinD1-negative and
cyclin D1–positive MCL patients. (C) Differential expres-
sion of miRNA between cyclin D1–negative and cyclin
D–positive MCL patients.
Figure 6. Correlation of miRNA expression with clinical outcome. (A) Differential miRNA expression between patients in the highest tertile (n  10) and lowest tertile
(n  10) of the proliferation signature (P  .05). (B) Kaplan-Meier curves of miR-636 and miR-424 showing significant (P  .05) association with OS on univariate analysis.
(C) Kaplan-Meier curves for risk groups using the 6-miRNA signature obtained for survival risk prediction using the method of Bair et al.29
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Discussion
In the present study, we profiled 187 patients with B-cell lym-
phoma and subsets of normal B cells with the goals of constructing
a reliable miRNA classifier for MCL, identifying miRNA-based
predictors of outcome, and determining possible roles of miRNA in
the pathogenesis of MCL. Because the putative cell of origin for
MCL is the naive, pre–germinal-center (pre-GC) B cell, we deter-
mined which miRNAs were associated with naive B cells and
investigated their expression pattern in other quiescent B cells.
These miRNAs included miR-150, miR-223, miR-29a, miR-29c,
miR-101, miR-320, miR-331, let-7b, miR-26a, and miR-342.
Some of these (miR-150, miR-29c, miR-101, miR-223, and
miR-320) have been described previously as being enriched in
naive B cells, using multiple platforms including deep sequenc-
ing.21,22 Some of these miRNAs may have a role in maintaining the
quiescent state or uncommitted status of B cells in peripheral
lymphoid organs. For example, the expression of miR-223 in naive
B cells has been shown to block the differentiation of naive B cells
into GC B cells by repressing LMO2 and MYBL1.21,22 Similarly,
miR-150 controls B1-cell expansion and the humoral immune
response in mice by targeting the key transcription factor MYB.32
However, the miRNA profile of MCL cells showed substantial
differences from that of naive B cells. Because MCL cells contain
stromal elements, we included the miRNA profiles of stromal cells
and T cells isolated from the tonsils to facilitate interpretation of
the data. Although some changes in miRNA profiles may occur
after culturing the stromal cells, many miRNAs are associated with
tissue of origin so we expected that this set of miRNAs would be
maintained. Although the stromal cells we generated represent only
a portion of the tumor microenvironment, the expression of this
stromal miRNA signature is clearly correlated with the abundance
of stroma in a tumor (Figure 1). After excluding stromal miRNAs,
there were still many overexpressed miRNAs compared with naive
B cells, suggesting that they may play a role in MCL. Of these,
miR-135a has been demonstrated to have an oncogenic role by
down-regulating adenomatous polyposis coli and activating the
WNT pathway in colorectal cancer,25 but in classic Hodgkin
lymphoma, it is associated with better prognosis and targets JAK2,
resulting in down-regulation of Bcl-xl.33 miR-21 has been shown to
be an oncomiR in a pre-B cell lymphoma mouse model,24 and its
direct targets include several tumor-suppressor genes (PTEN,
PDCD4, and ANP32A).34 Similarly, the other up-regulated miR-
NAs (miR-10a and miR-10b) are oncomiRs that induce cell
motility and invasiveness by suppressing HOXD10.23 Interestingly,
in the present study, miR-10a was down-regulated in cluster
C (miRNA clustering Figure 3A-B) of MCL, and the HOX10-
induced genes were correspondingly enriched in the same group
when assessed by GEP. Consequently, low expression of miR-10a
was associated significantly with better survival in MCL by
univariate analysis (P  .03). Conversely, a few highly up-
regulated miRNAs in naive B cells, such as miR-150, miR-223,
and miR-342-5p, were also down-regulated in activated peripheral
blood B cells as in MCL cells, suggesting that they regulate B-cell
activation and that their down-regulation may be important in
terminating quiescence.
Our analysis identified a robust MCL miRNA classifier, which
included 6 up-regulated and 13 down-regulated miRNAs. The
classifier was able to separate MCL from other aggressive lympho-
mas accurately in 29 of 30 patients with a  90% probability.
Interestingly, 2 DLBCL patients were misclassified, but after
further morphologic examination, these 2 patients were diagnosed
as having the paraimmunoblastic variant of CLL and showed
similarity to MCL and SLL in their miRNA expression profiles. It is
interesting that these 2 highly proliferative patients still retained
sufficient similarity to MCL and SLL patients to be included in this
category rather than in the DLBCL/BL category. The analysis of
miRNA profiling performed on the corresponding FFPE tissues
showed similar results, demonstrating that the classifier performed
with similar accuracy in FFPE tissues.
Of the miRNAs in the classifier, we observed a 45-fold
down-regulation of miR-150 after differentiation of naive B cells to
CB cells. This observation suggests that miR-150 is a stage-specific
marker of naive B cells and may block the transition of naive
B cells to CB cells by down-regulating MYB.32 The association of
miR-184 with MCL may be attributed in part to its presence in
15q25.1, which is frequently gained or amplified ( 20%) in MCL9
and has been associated functionally with cell proliferation and
tumorigenesis.26 The other up-regulated miRNAs in the classifier
with known roles include miR-135a33 and miR-363,31 which have
been implicated in oncogenesis. However, the classifier contains
highly selected miRNAs, and the study of miRNAs in tumor
biology is more appropriately performed in the context of differen-
tially expressed miRNAs compared with the normal counterpart
and other B-cell lymphomas. Because the function of miRNAs may
be context dependent, their reported functions may need to be
validated in the cell type of interest.
In the present study, we have demonstrated that the miRNA
classifier for cyclin D1–positive MCL was very similarly expressed
in cyclin D1–negative patients in FFPE tissues, which were all
classified as MCL. There were, however, sufficient differences that
these 2 groups of patients tended to form their own clusters when
analyzed as a group. Of the differentially expressed miRNAs,
miR-155 was up-regulated whereas 6 miRNAs down-regulated by
MYC, including tumor suppressor miR-15a, were down-regulated
in cyclin D1–negative MCL patients. Cyclin D1–positive patients
showed significant up-regulation of miR-27, miR-101, miR-142-
5p, miR-19a, miR-19b, and 2 stroma-associated miRNAs, miR-126
and miR-143, compared with their cyclin D1–negative counter-
parts, suggesting a subtle distinction in their pathogenesis. How-
ever, different miRNAs may affect the same oncogenic pathways
through different mechanisms, as illustrated by miR-155 (up-
regulated in cyclin D1–negative patients) and miR-19 (up-
regulated in cyclin D1–positive patients) that may both activate the
PI3K pathway by suppressing SHIP1 and PTEN, respectively.
The SLL patients showed an miRNA expression pattern similar
to that of MCL patients, probably due in part to their low
proliferation, the non-GC B-cell origin of the neoplastic cells, and
their low stromal content, although the majority of patients do form
a separate cluster (Figure 1A). Most SLL patients can also be
differentiated from MCL patients with an miRNA classifier, with
miR-150 showing marked up-regulation in SLL, whereas 23 of the
26 other miRNAs showed higher expression in MCL, including
miRNAs associated with the proliferation signature (miR-106b-25
and miR-20b), prosurvival signal (miR-181a) via Bim down-
regulation,35 and 15q amplification (miR-184).9 Only one patient of
each was misclassified into the other category; the misclassified
SLL patient was an aggressive paraimmunoblastic variant, and the
misclassified MCL patient belongs to cluster C, which included
more indolent patients.
By unsupervised HC, the miRNA expression profile segregated
the MCL patients into 3 clusters that appeared to have biologic and
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clinical differences. Cluster A showed high expression of prolifera-
tion-related miRNAs, including the miR17-92 cluster30 and its
paralogs miR-106a-363 and miR-106b-25, which is also consistent
with higher expression of proliferation-related genes. Contrary to
cluster A, cluster C showed higher expression of stroma-associated
miRNAs, including miR-23a, miR-23b, let-7c, let-7-b, and miR-
125b and miRNAs with growth-inhibitory functions, including
miR-1, miR-133b,16 and miR-10b.18 GEP analysis also showed low
expression of proliferation-related genes and, interestingly, showed
high expression of transcripts encoding extracellular matrix-related
proteins (ECM2, EDN1, EGFR, EPS8, ITGA9, and PDGFD).
Further examination of these gene signatures in another MCL
cohort (n  82) generally validated these findings. Most of the
patients showed an inverse correlation between the signature enriched
in proliferation-associated genes versus stromal-associated genes,
and a high ratio of these 2 signatures was associated with poorer
survival. This observation suggests that the stroma may have
influence on tumor cell proliferation. The influence of the tumor
microenvironment on the outcome of patients with follicular
lymphoma has been demonstrated previously.36 Similarly, in
DLBCL, the “stromal-1 signature,” which is related to extracellular-
matrix deposition and mesenchymal and histiocytic cells, is
associated with favorable outcome.37 We have also reported
recently the contribution of the stromal signatures in the prognosis
of patients with angioimmunoblastic T-cell lymphoma.38 The
results of the present study suggest that a group of stroma-
associated miRNAs may define a more indolent group of patients
and warrant further investigation.
These MCL subgroups also showed differences in the expres-
sion of distinct signaling pathways when the associated GEP data
were examined. Cluster C showed enrichment of pathways associ-
ated with “stemness/quiescence,” such as WNT and TGF-
signaling, whereas cluster B appeared to be associated with higher
genotoxic stress (enriched ATM and p21 pathway genes). Because
of the reported role of WNT signaling in CLL39 and of the nuclear
staining of -catenin in neoplastic cells in 52% of MCL patients,40
we further investigated the expression of -catenin by immunohis-
tochemistry. In our patients, -catenin seemed to be mostly
localized in stromal elements. Neither we nor our collaborators
(E.C., personal communication) were able to demonstrate nuclear
expression of -catenin in neoplastic MCL cells, suggesting that
WNT activation may be attributed mostly to stromal components in
cluster C patients. The effects of WNT signaling on B cells are
complex, with some studies indicating that WNT signaling is
important in the proliferation of pro- and pre-B cells.41 WNT
signaling has also been reported to be prosurvival in GC B cells and
in CLL cells, but several other studies have reported that activation
of canonical WNT signaling in stromal cells inhibits B-cell
lymphopoiesis42 and WNT5a can signal through noncanonical
WNT/Ca2 pathways to negatively regulate B-cell proliferation.43
A more recent study has shown that activation of canonical WNT
signaling in stromal cells blocks the proliferation and production of
B and NK cells, as well as plasmacytoid dendritic cells,44 and
induces the expression of extracellular matrix genes. Because
WNT signaling is observed in the least proliferative subset of MCL
and because -catenin appears to be found in stromal cells, the
possible role of microenvironmental miRNA in generating inhibi-
tory signals to neoplastic MCL-cells is intriguing and warrants
further experimental studies.
Among the miRNAs up-regulated in the high-PS group,
miRNAs from the miR17-92 cluster and its 2 paralogs have been
confirmed in promoting cell proliferation and inhibiting apopto-
sis.30 In our previous study, we have also shown that miR17-92
targets PHLPP2, an important negative regulator of the PI3K/AKT
pathway, in addition to PTEN and BIM, and overexpression of
miR17-92 leads to constitutive activation of PI3K/AKT pathway
and also chemoresistance in MCL cell lines.30 In previous studies,
high expression of miR17-5p and miR-20b in MCL was associated
with short OS.12,13 In contrast, low expression of miR-29, the target
genes of which includes CDK6, was associated with a poor
prognosis.11 We observed that miR17-92 clusters and its paralogs,
miRNA-363, and some of the other miRNAs were correlated with
PS (Figure 6A). We generated a 6-miRNA prognosticator for MCL
that worked independently of the PS. Of the 6 miRNAs, miR-222
and miR-146a showed a higher difference ( 3-fold) in expression
between the 2 prognostic groups. miR-146a27 is repressed and
miR-22245 is induced by MYC, and these miRNAs showed the
expected correlation with MYC mRNA expression, suggesting that
MYC may play a role in MCL prognosis, which is consistent with
previous findings.46 The effect of MYC may be mediated in part
though the control of miRNA expression. miR-222, which is
coexpressed as a cluster with miR-221, targets the tumor-
suppressor p27Kip147 and loss of miR-146a promotes tumorigenesis
in mice.48 Aside from miRNAs that are correlated with the PS, our
study suggests that there are other miRNAs that could serve as
predictors of survival. However, because of the limited number of
patients in the present study, this miRNA prognosticator will need to be
validated and refined in future studies with more MCL patients,
particularly in a clinical trial setting.
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Supplemental Materials and methods 
Normal primary B-cells and cell lines 
Normal naïve B-cells, centrocytes (CC), centroblasts (CB) and T-cells were purified with > 90% purity 
from reactive tonsils using magnetic beads as described previously1.  Lymphoid cell lines from human 
DLBCL (DHL16, SuDHL6, KARPAS1106, OCI-Ly3 and OCI-Ly10), BL (DAUDI, RAJI), MCL (JVM2 
and JEKO), classic Hodgkin disease (L428) and myeloma (U226) were used for comparison.  
The stromal cells were isolated from minced human tonsils digested with 2 mg/ml collagenase type IV 
(Worthington Biochemical, Freehold, NJ) and 0.1 mg/ml DNase I (Sigma-Aldrich, St. Louis, MO) as 
done previously2, and cultured in RPMI-1640 medium with 10% FCS for one week. The adherent cells 
were harvesting for miRNA profiling.  
 
In-vitro B lymphocyte activation 
MACS-purified CD19+ peripheral blood (PB) B-cells were activated in-vitro at a density of 1x106 
cells/ml with 10μg/ml F(ab')2 goat antihuman IgM (Southern Biotech, Birmingham, AL) and 10 ng/ml 
interleukin-4 (R&D Systems, Minneapolis, MN) for 24 hours in RPMI-1640 medium supplemented with 
10% FBS plus L-glutamine and penicillin-streptomycin (Invitrogen, Inc).  
 
RNA isolation and miRNA and gene expression profiling 
Total RNA for miRNA profiling was extracted from cryopreserved tissues utilizing four 20 μM sections 
(~1 cm2 surface area) with the mirVana™ miRNA isolation kit, and from FFPE cases utilizing 2 cores 
(~1mm diameter) with the recoverAllTM.Total nucleic acid isolation kit according to the manufacturer’s 
instructions (Ambion, Austin, TX). Reverse-transcription was carried out with 300ng or 100ng of total 
RNA from cryopreserved or FFPE samples, respectively, with Megaplex™ RT Primers and enzyme kit, 
with a subsequent step of pre-amplification (12 cycles) using Megaplex™ PreAmp Primers as 
recommended by the manufacturer (ABI-Foster City, CA). The pre-amplified cDNAs were loaded onto 
 2
384-well format microRNA assays plates (Taqman® human micoRNA A array V2.0- ABI, CA), and 
qRT-PCR was performed on a 7900HT Fast Real-Time PCR System (ABI-Foster City, CA). The 
threshold cycle (CT) was defined as the fractional cycle number at which the fluorescence exceeds the 
fixed threshold of 0.1 with automatic baseline using the RQ Manager-1.2 software (ABI-Foster City CA).  
The raw data were uploaded into BRB-ArrayTools (version4.2.0)3 for analysis. Briefly, we performed 
global median normalization strategy for the entire data set prior to any further analysis.  To select 
miRNAs for analysis, we used three approaches (i) exclude miRNA showing minimal variation across the 
arrays from analysis. This was performed by including miRNAs whose expression differed by at least 2 
fold from the median in at least 10% of the cases (ii) exclude miRNAs if the log intensity variation was 
not significant (p>0.05) compared to the median of all the variances. (iii) CT =30 or higher were used a 
threshold for the minimum level of expression. The miRNA classifiers for MCL and SLL were 
constructed using a Bayesian algorithm that estimated the probability of a case belonging to one subtype 
of B-cell lymphoma compared to other subtype as shown in BRB-ArrayTools3. In our series, miRNAs 
were selected at a significance of p<0.005 and a mean fold-difference of >4 between the two groups for 
Bayesian classification, and arbitrarily chose >90% probability as the cutoff to classify cases. 
Classification precisions were evaluated using leave-one-out cross-validation (LOOCV)3 as described in 
BRB ArrayTools software and described in detail previously3,4. Differential miRNA expression was 
evaluated using random-variance t-test and significance-analysis-of-microarrays (SAM) using BRB-
ArrayTools. The differential miRNAs selected showing expression level difference of at least 4-fold at 
significance of p<0.005 and false discovery rate of <0.2% in normalized signal intensities as utilized in 
BRB ArrayTools were further analyzed. 
Total RNA for GEP was extracted using the Allprep DNA/RNA isolation kit (Qiagen Inc.Valencia 
CA). We used HG-U133 plus-2 arrays (Affymetrix, Inc) for GEP according to manufacture’s instruction. 
The raw data were uploaded into BRB-ArrayTools3 and differential gene expression was determined 
 3
using the above-mentioned statistical tests. Gene-set-enrichment-analysis (GSEA) computational 
programs were utilized for pathway analysis in GEP data5. 
The GEP of MCL validation cohort (n=82) included in this study has been previously reported 6. The 
assays have been updated from same cases using HG U133 A and B chips (Affymetrix). 
 
Immunological and fluorescence in-situ hybridization (FISH) analysis 
Immunohistochemical stains for CD3, CD5, CD10, CD20 and CD23 were performed on FFPE tissue 
sections as described previously7. For immunohistochemical staining of cyclin D1, the rabbit monoclonal 
antibody SP4 against cyclin D1 (Neomarkers, Fremont, CA) was used on a Ventana ES automated 
immunostainer (Ventana Biotek, Tucson, AZ) with a streptavidin-biotin peroxidase detection system. 
Positivity was defined as a strong nuclear staining in more than 50% of the neoplastic cells. The t 
(11;14)(q13;q32) was detected using a commercially available LSI IGH/CCND1 double-color, double-
fusion probe (Vysis, Downers Grove, IL) according to the manufacturer's instructions.  
 
Survival analysis 
Event-free survival (EFS; event = progression or death from any cause after the start of chemotherapy) 
and overall survival (OS; event = death from any cause) were estimated using the Kaplan-Meier method, 
and differences were assessed using the log rank test.  The above statistical analyses were performed 
using SPSS software version-11. The survival risk groups were constructed using the supervised principal 
component method of Bair et al.8, and the predictive value of the model was evaluated by LOOCV using 
BRB-ArrayTools. 
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 Supplemental Figure legend 
Supplemental Figure-1: OS and EFS of MCL and SLL cases showed poorer outcome in MCL cases. 
 
Supplemental Figure-2: Differential expression of microRNAs in 3 normal subsets of B-cell, and a 
representative miRNA signature associated with naive B-cell is also expressed in CC.  
 
Supplemental Figure-3: Representative case with high stromal miRNA signature (Cluster-C) showing 
expression of β-catenin [A, B(H&E)] in stromal and endothelial cells. The vast majority of tumor cells are 
negative, whereas cases with high proliferation signature (cluster-A) show only occasional cell weakly 
positive for beta-catenin [C, D(H&E)]. 
 
Supplemental Figure-4:  Refinement of a GEP based prognostic signature (A) Derivation of 71 probe set 
with two gene signatures, one enriched in proliferation related genes (Signature-1) and the other enriched 
in stroma-related genes (Signature-2) in training data set (n=30 MCL cases). Inverse correlation of the 
expression level of two gene signatures (means) and association of signature-1: signature-2 (ratio of 
means) with EFS (B) Analysis of the two gene signatures in validation data set (n=82 MCL cases), and 
inverse correlation of the two gene signature expression levels (mean) and association of the two 
signatures ratio (of means) with OS. 
 
 
Supplemental Table 1a: Clinical characteristics and pathological features of cyclin D1-positive MCL 
cases 
 
Case NO Sex Age 
(years) 
B-cell marker 
demonstrated 
CD5 or 
CD43* 
Cyclin D1 expression / 
CCND1 translocation** 
GEP-based 
proliferation 
signature***  
MCL1 Male 72.6 CD20  - + 8 
MCL2 Male 78.3 CD20  + + 7.86 
MCL3 Male 58.5 CD19 /CD22  + +/** 7.72 
MCL4 Male 63.7 CD20 + +/** 8.05 
MCL5 Male 59.7 CD19 /CD22  + +/** 7.96 
MCL6 Male 73.9. CD19 /CD22  - + 8.34 
MCL7 Male 51.9 CD20 /CD22  + +/** 8.02 
MCL8 Male 76.3 CD19 /CD22  + +/** 9.07 
MCL9 Male 58.4 CD19 /CD22  - + 8.12 
MCL10 Male 62.7 CD19 /CD22  + + 7.81 
MCL11 Male 44.5 CD20 /CD22  + + 7.95 
MCL12 Male 64.9 CD20 /CD79a  + + 8.38 
MCL13 Male 55.4 CD20   +* +/** 8.02 
MCL14 Male 75.1 CD20   - + 7.33 
MCL15 Male 84.7 CD20   + + 7.6 
MCL16 Male 75.6 CD20   + +/** 8.09 
MCL17 Male 71.6 CD20   + + 7.48 
MCL18 Male 59.9 CD20   + + 7.16 
MCL19 Male 46.8 CD20   + +/** 8.05 
MCL20 Male 70 CD20   + +/** 8.23 
MCL21 Male 60.5 CD20   - + 8.1 
MCL22 Male 36.9 CD20   + + 8.91 
MCL23 Male 88.1 CD20   + + 8.82 
MCL24 Male 70.9 CD20   + +/** 7.33 
MCL25 Male 60.4 CD20   + + 7.55 
MCL26 Female 80.2 CD20   +* + 8.05 
MCL27 Female 58.8 CD20 /CD79a  +* + 8.45 
MCL28 Female 49.3 CD20   + + 8.05 
MCL29 Female 56.7 CD20   + +/** 8.06 
MCL30 Female 64.9 CD20   + +/** 6.99 
 
* indicates CD43 expression  
** by FISH  
*** median values with log2 signal intensities 
Supplemental Table 1b: Immunophenotype of cyclin D1-negative MCL cases 
 
Case NO Sex Age 
(years) 
CD5 CD20 SOX11 CD23 Cyclin
D1 D2 D3
MCL-N1 Male 51 + + + - (-) + - 
MCL-N2 Male 69 + + + - (-) ND ND 
MCL-N3 Female 60 + + + - (-) ND ND 
MCL-N4 Male 65 + + + ND (-) + - 
MCL-N5 Male 60 + + + + weak (-) - + 
MCL-N6 Female 54 + + + - (-) + - 
MCL-N7 Male 61 + + + - (-) - + 
Supplemental Table 2: GSEA analysis in three MCL clusters 
 
 
 GSEA Comparison 
between groups 
Enrichment in A Enrichment in B Enrichment in C
 
 
Cluster 
A vs B 
 
Proliferation related 
signatures 
 
8 of 10 signatures p<0.03 and 
FDR<0.25 
EGF pathway
VEGF-induced signature 
IL6 induced 
Hypoxia induced 
Notch-1 
TGF-beta induced 
Hox-10 induced stroma 
CD31negative quiescent/stem 
HSC stem cell like 
  
 
 
Cluster 
 
A vs C 
Proliferation related 
signatures 
 
 
  VEGF-induced signature 
IL6 induced 
Hypoxia induced 
Notch-1 
WNT-pathway 
Hox-10 induced stroma 
CD31negative quiescent/stem 
HSC stem cell like 
STAT5A induced signature 
TGF-beta induced 
 
Cluster 
 
C vs B 
  P21 regulated signature 
TGF-beta induced 
ATM pathway 
TCR pathway 
BCR pathway 
IL4 signal transduction 
WNT pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bolded pathways are not shared between groups B and C when they are compared with group A 
 
 
 
 
 
 
 
 
Supplemental Table 3: miRNA prognostic signature identified using Bair’s principle 
 
miRNA  OS (p-value) EFS (p-value) 
129-3p 0.0037 0.0079 
135a 0.0076 0.0043 
146a 0.0039 0.0000 
222 0.0007 0.0096 
424 0.0020 0.0004 
450-5p 0.0027 0.0010 
 
6 miRNAs selected by fitting Cox proportional hazards models (α= 0.01) 
The percent of variability explained by the first 3 principal components is 90.307 
The p-value in the table is testing the hypothesis that expression data is predictive of survival.  
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